Want to see JP:4577 full AI Analyst Report?
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥1,120.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)66.48K
Market Cap
¥38.95B
Enterprise Value¥44.71B
Total Cash (Recent Filing)¥954.00M
Total Debt (Recent Filing)¥9.29B
Price to Earnings (P/E)12.3
Beta0.22
Next Earnings
Jan 08, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.99%
Share Statistics
EPS (TTM)107.46
Shares Outstanding28,854,880
10 Day Avg. Volume74,440
30 Day Avg. Volume66,479
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.65
Price to Sales (P/S)0.68
P/FCF Ratio6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)88.7
Revenue Forecast (FY)¥54.00B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a substantial equity buffer reduce financial strain during demand or pricing volatility. This gives Daito greater resilience, preserves borrowing capacity, and supports continued investment or other capital allocation choices over the next several quarters.
Improved Cash GenerationThe return to positive operating and free cash flow is an important improvement in internal funding capacity. If maintained, it can support investment, dividends, or debt management without relying as heavily on external financing, strengthening business flexibility.
Positive Current ProfitabilityDespite weaker results than the 2022–2023 peak, Daito remains profitable at both the net income and operating levels. Positive margins provide a base for reinvestment and indicate that the pharmaceutical business still generates earnings rather than operating at a loss.
Bears Say
Sharp Revenue ContractionA contraction of this magnitude is a material challenge to the company’s growth profile and future operating leverage. Prolonged top-line weakness could reduce scale benefits, constrain investment capacity, and make it harder for earnings to return to prior peak levels.
Margins Below Prior PeakThe decline from earlier profitability peaks suggests that current earnings power is not yet fully restored. Lower operating margins leave less room to absorb pricing or demand pressure and may limit the company’s ability to convert revenue recovery into proportionately stronger profits.
Unproven Cash-flow DurabilityAlthough cash generation has recently turned positive, the multi-year history of negative free cash flow means the improvement has not yet demonstrated consistency. Moderate conversion from earnings and operating cash flow below EBIT indicate that working-capital or timing effects remain relevant.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥1120.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥38.95B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jan 08, 2027 which is in 76 days.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Daito Pharmaceutical Co., Ltd. released its earnings results on Oct 14, 2026. The company reported ¥24.66 earnings per share for the quarter.
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥22.5 which represents an annual dividend yield of 2.99%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daito Pharmaceutical Co., Ltd. reported an EPS of ¥24.66 in its last earnings report. Following the earnings report the stock price went down -1.394%.
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―